newsfilter
← Latest News
GlobeNewswire·

Spero Therapeutics Announces First Quarter 2025 Operating Results and Provides a Business Update

Pre-specified interim analysis of the ongoing Phase 3 PIVOT-PO clinical trial of tebipenem HBr in complicated urinary tract infection (cUTI), including acute pyelonephritis (AP), on track to be completed in Q2